Inactivation of TP53 tumor suppressor gene is the most frequent molecular alteration in NSCLC, involving up to 60% of cases. Furthermore, TP53 mutational spectrum is related to the type of mutagen exposure, as well as racial and/or diet dierences. Nearly 95% of TP53 perturbations aect codons included within exons 5 ± 8 which encode for almost the entire DNA-binding domain. In this study we addressed the possible prognostic value of the molecular alterations identi®ed in exons 5 ± 8 of the TP53 gene in DNAs from 151 paran-embedded NSCLC sections corresponding to 59 Spanish and 92 Polish stage I-IIIA resected patients. PCR/single-strand conformation polymorphism (SSCP) analysis revealed that the occurrence of TP53 exon 5 ± 8 mutations was 17/59 (29%) in the Spanish cohort and 17/92 (18%) in the Polish group. However, when DNA sequencing analysis was performed, these frequencies were reduced because of the presence of SSCP-false positive, intronic and silent mutations and polymorphisms. Fifteen of the 59 Spanish NSCLC tumors (25%) harbored TP53 mutations aecting exons 5 ± 8 coding sequences, whereas only 12 of 92 Polish neoplasms (13%) contained alterations in the central hydrophobic region of p53. Our results indicate that the occurrence of TP53 mutations aecting exon 5 ± 8 coding sequences in some European NSCLC populations may be lower than previously reported, and that the TP53 mutational patterns of these cohorts dier somewhat. The Spanish NSCLC patients contained missense mutations (9/59, 15%) and a relatively high percentage of null mutations (5/59, 8%) while the Polish patients mostly harbored missense mutations (9/92, 10%) and only one tumor contained a null type (1/92, 1%). Moreover, most TP53 missense mutations in the Spanish group were located outside the conserved regions, whereas the same mutations in the Polish group aected conserved amino acids. Furthermore, the Polish patients harbored a high percentage of G?A transitions (most of them at non-CpG sites), while G?T transversions were predominant in the Spanish group. Our ®ndings suggest that there may be dierent racial or exogenous factors in these two populations which may help to explain both the distinct TP53 mutational pattern and the lower frequency obtained in the Polish group. The presence of missense mutations did not confer a worse clinical outcome in these subsets of NSCLC patients. However, patients whose tumors contained null TP53 gene mutations had a 5 month median disease-free survival time in contrast with 42 months in those patients without mutations (P=0.008). These ®ndings suggest that loss of p53 function may enhance tumor progression in NSCLC patients independently of whether dominant negative TP53 missense mutations are present.
Inactivation of TP53 tumor suppressor gene is the most frequent molecular alteration in NSCLC, involving up to 60% of cases. Furthermore, TP53 mutational spectrum is related to the type of mutagen exposure, as well as racial and/or diet dierences. Nearly 95% of TP53 perturbations aect codons included within exons 5 ± 8 which encode for almost the entire DNA-binding domain. In this study we addressed the possible prognostic value of the molecular alterations identi®ed in exons 5 ± 8 of the TP53 gene in DNAs from 151 paran-embedded NSCLC sections corresponding to 59 Spanish and 92 Polish stage I-IIIA resected patients. PCR/single-strand conformation polymorphism (SSCP) analysis revealed that the occurrence of TP53 exon 5 ± 8 mutations was 17/59 (29%) in the Spanish cohort and 17/92 (18%) in the Polish group. However, when DNA sequencing analysis was performed, these frequencies were reduced because of the presence of SSCP-false positive, intronic and silent mutations and polymorphisms. Fifteen of the 59 Spanish NSCLC tumors (25%) harbored TP53 mutations aecting exons 5 ± 8 coding sequences, whereas only 12 of 92 Polish neoplasms (13%) contained alterations in the central hydrophobic region of p53. Our results indicate that the occurrence of TP53 mutations aecting exon 5 ± 8 coding sequences in some European NSCLC populations may be lower than previously reported, and that the TP53 mutational patterns of these cohorts dier somewhat. The Spanish NSCLC patients contained missense mutations (9/59, 15%) and a relatively high percentage of null mutations (5/59, 8%) while the Polish patients mostly harbored missense mutations (9/92, 10%) and only one tumor contained a null type (1/92, 1%). Moreover, most TP53 missense mutations in the Spanish group were located outside the conserved regions, whereas the same mutations in the Polish group aected conserved amino acids. Furthermore, the Polish patients harbored a high percentage of G?A transitions (most of them at non-CpG sites), while G?T transversions were predominant in the Spanish group. Our ®ndings suggest that there may be dierent racial or exogenous factors in these two populations which may help to explain both the distinct TP53 mutational pattern and the lower frequency obtained in the Polish group. The presence of missense mutations did not confer a worse clinical outcome in these subsets of NSCLC patients. However, patients whose tumors Introduction Lung cancer (LC) is the leading cause of cancer death in the US, and a similar trend is seen in Europe (Bon®ll et al., 1996) . Non-small cell lung cancer (NSCLC) is the most common type of LC, representing 80% of cases and consisting of adenocarcinoma, squamous cell carcinoma, large-cell carcinoma, and some rare histological types. Although tumor extent is one of the most signi®cant prognostic parameter considered, the molecular pathogenesis of NSCLC must be understood in order to discover other potential, independent factors in¯uencing outcome. Inactivation of TP53 tumor suppressor gene emerge as the most frequent molecular disturbance in human neoplasms, although frequency and type of mutation dier substantially among cancers. Particularly in NSCLC, the TP53 mutational frequency is considerably variable among dierent populations and studies, ranging from 20 ± 60% (Kishimoto et al., 1992; Lee et al., 1994; Ryberg et al., 1994; Takagi et al., 1995) .
The TP53 tumor suppressor gene encodes for a 53 KD DNA sequence-speci®c transcription factor with multiple functions: gene transcription, DNA synthesis and repair, apoptosis and angiogenesis (Harris, 1996; Ko and Prives, 1996) . In the cellular context, the biological behavior of p53 protein can be modulated by binding to cellular and oncoviral proteins as well as by alterations in TP53 sequence. Therefore, it has been suggested that detection of TP53 abnormalities may have diagnostic, prognostic, and therapeutic implications (Harris and Hollstein, 1993) . In NSCLC particularly, the clinical value of TP53 alterations as a prognostic tool is still a controversial issue. Some studies indicate that p53 immunohistochemistry is indicative of a poor prognosis (Quinlan et al., 1992; Carbone et al., 1994) , while others demonstrate the contrary (Lee et al., 1995) . Similarly, the potential role of TP53 mutations is also debatable. Carbone et al. (1994) did not associate these perturbations with major aggressiveness in NSCLC patients, while other investigators observed the opposite eect (Horio et al., 1993; Mitsudomi et al., 1993) . However, these investigations did not analyse the TP53 mutational pattern, and the interpretation of the single use of screening methods without DNA sequencing in these studies is dicult. Although there are tumors that have lost one TP53 allele or contain a mutation that abrogates p53 function (null phenotype), most TP53 perturbations found in human neoplasms are of missense type. These mutations normally behave as dominant negative oncogenes, requiring only one mutated TP53 copy to inhibit cell proliferation by complexing the wild-type form (Farmer et al., 1992; Kern et al., 1992) . Nearly 90 ± 95% of TP53 mutations reported in human cancers have been detected in exons 5 ± 8 and their intervening introns, the latter resulting in deleted exons and the formation of truncated proteins (Hollstein et al., 1991; Caron de Fromentel and Soussi, 1992; Kishimoto et al., 1992; Mitsudomi et al., 1992) . Most of this region (exons 5 ± 8) includes the sequence speci®c DNA binding domain of the protein, where the vast majority of alterations are present. Remaining mutations are outside the central core of the protein, aecting the transactivation domain (amino terminal region) and the oligomerization and DNA-damage binding domains (carboxy terminal region). Surprisingly, most of them are of null type generating a non-functional protein and few cases contain missense mutations (Hartmann et al., 1995) . Unlike RB and APC tumor suppressor genes which are inactivated by null mutations, most TP53 mutations are of missense type. These mutations normally stabilize p53 protein, leading to its accumulation, which can then be detected by immunohistochemistry. Nuclear overexpression of p53 protein has been routinely used as a simple method of screening tumor samples for the presence of TP53 alterations, although this presence is not always associated with a mutational change (Wynford-Thomas, 1992; Dix et al., 1994) .
A large body of evidence indicates that several factors, including endogenous metabolites and exogenous carcinogen compounds can induce DNA damage (Zarbl et al., 1985) . The nature and the location of the mutational change within the TP53 gene dier greatly among tumors of dierent histological type which may be a re¯ection of some DNA genotoxic agents (Greenblatt et al., 1994) . The TP53 mutational spectra of cancer patients belonging to dierent populations, or in groups of patients exposed to particular DNA mutagens has been studied by several investigators (VaÈ haÈ kangas et al., 1992; Takeshima et al., 1993; Thorlacius et al., 1993; Saitoh et al., 1994; Shiao et al., 1995; Takagi et al., 1995; Taylor et al., 1996; Liloglou et al., 1997) . However, as far as we know, there are no studies comparing the TP53 mutational pattern in dierent European NSCLC patient population groups, as well as investigations demonstrating a correlation between certain TP53 mutations and prognosis in NSCLC. We were therefore prompted to examine a surgical series of 59 Spanish and 92 Polish NSCLC patients (stage I, II and III, according to TNM classi®cation) for the presence of molecular alterations in this gene in order to determine: ®rst, the occurrence of TP53 alterations aecting exon 5 ± 8 coding sequences in both populations and their relationship to clinical parameters and outcome; second, whether TP53 mutational clustering occurred; and third, whether dierences in the patterns of mutations existed in NSCLC patients from geographically distinct European populations (Spain and Poland).
Results

TP53 mutational frequency
Paran embedded tumors from one hundred ®fty-one completely resected NSCLC patients who did not receive adjuvant treatment were evaluated. Median age at diagnosis was 61.6 years (range 33 ± 82); 95% were smokers. Squamous cell carcinoma was the most common histological subtype (64%), followed by adenocarcinoma (30%) and large cell carcinoma (5%) ( Table 1) . These NSCLC specimens were screened by PCR/SSCP for the presence of TP53 mutations in exons 5 ± 8. Seventeen of 59 (29%) Spanish and 17 of 92 (18%) Polish samples displayed mobility-shifts in the PCR/SSCP autoradiograms. All tumor DNA with suspicious migratory bands on SSCP were analysed by direct sequencing to assess TP53 genotypes in exons 5 ± 8. In the Polish group of patients, two samples were SSCP-false positive, containing in fact wild-type alleles. Furthermore, three showed point mutations at introns 6 and 7 that did not alter splice sites, leading to a (4) 9 (100) 0 (0) 5 (100) 0 (0) 67 (82) 15 (18) 8 (89) 1 (11) 1 (100) 0 (0) Histology SCC AC LCC 29 (78) 12 (70) 4 (80) 5 (14) 3 (18) 1 (20) 3 (8) 2 (12) 0 (0) 53 (88) 26 (90) 3 (100) 7 (12) 2 (7) 0 (0)
22 (81) 8 (73) 15 (72) 4 (15) 3 (27) 2 (9) 1 (4) 0 (0) 4 (19) 44 (92) 12 (75) 26 (93) 4 (8) 4 (25) 1 (4) 0 (0) 0 (0) 1 (3) SCC, squamous cell carcinoma; AC, adenocarcinoma; LCC, large cell carcinoma TP53 mutational pattern in Spanish and Polish NSCLC patients JM de Anta et al decrease in the total number of TP53 mutations to 13% in these patients. Furthermore, two tumors in the Spanish group harbored polymorphisms at codon 213 (CGA?CGG) which did not alter the encoded arginine (samples 7 N1 and 12 N1). Overall, the percentage of gene alteration was 25%. There were no dierences between clinicopathological factors and TP53 status (Table 1) .
TP53 mutational pattern
When both series were examined separately, some dierences in the nature of TP53 mutations surfaced. In Spanish NSCLC specimens, nine (15%) were missense, one (2%) silent and ®ve (8%) null mutations. Of these changes, one (2%) was nonsense type ( Figure 1 ) and four (7%) frameshift mutations, two (3%) deletions and two (3%) insertions. Conversely, all TP53 mutations in the Polish cohort were single-base substitutions, nine (10%) missense, two (2%) silent and one (1%) nonsense mutations ( Table  2) . There were some dierences in the nature of the TP53 missense mutations in both groups of patients. Although TP53 mutations in Spanish patients were relatively dispersed, 22% of missense changes aected codon 151, whereas a further 22% involved codon 196. Moreover, there was a paucity of missense changes aecting conserved amino acids in the Spanish group of NSCLC patients, with only one mutation aecting codon 176 at domain III (Table 3) . Therefore, eight mutations aected non-conserved amino acids (three mutations were located between domains II and III (amino acids 142 ± 171), four between regions III and IV (amino acids 181 ± 234) and one beyond domain V (starting amino acid 286) (Figure 2) . Conversely, most TP53 missense mutations in Polish NSCLC specimens were identi®ed in domains IV and V (8/9, 89%), whereas 1/9 (11%) of those gene alterations involved a non-conserved amino acid (Table 4 ). In the Polish patients, TP53 mutational clustering at codons 245 and 282 occurred, 44% of missense mutations aected codon 245 and 22% codon 282. Single-nucleotide substitutions at codons 245 and 248 (5/9, 56%) are hotspots in human cancer, but only one (patient 80, codon 248) (1/9, 11%) has previously been considered a hotspot in LC (Greenblatt et al., 1994) (Table 4 ).
The nature of any nucleotide perturbation was also monitored. DNA sequencing analysis revealed that the Spanish group of NSCLC patients contained a slight predominance of transversions (55%) versus transitions (45%) ( Table 5 ). The most frequent type of transversions was G?T (36%), whereas G?A was the most common transition (27%), all of them located at non- (Table 5) . Conversely, G?T transversions were observed at a lower frequency in Polish tumors (27%). These patients exhibited an abundance of G?A transitions (46%), mostly at non-CpG nucleotides (40%) ( Table 5 ).
TP53 status and clinical outcome
When we searched for correlations between certain TP53 genotypes (missense, null, versus wild type) and clinical outcome in the whole group of patients, the presence of TP53 null mutations were associated with a worse disease-free survival. Median disease-free survival time for patients with null mutations was 5 months compared to 42 months in those patients without mutations (P=0.008) (Figure 3 ). The clinical behavior of patients containing null mutations also diered from those harboring missense mutations (5 months versus 24 months of median disease-free survival time), although this dierence did not reach statistical value. In those patients harboring missense perturbations, we were unable to demonstrate dierences in prognosis between those containing mutations aecting conserved amino acids and those including nucleotide substitutions at non-conserved residues (data not shown). Furthermore, there were no dierences in overall survival among the group of patients without mutations and those with missense mutations (median survival time 38 months and 45 months, respectively). Looking for stronger predictive factors, and using multivariate analysis, stage IIIA was the only signi®cant independent factor in¯uencing survival (hazard ratio 1.7; P50.001). 
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Discussion
Tumor suppressor genes are inactivated by multiple mechanisms. Ablation of genes like RB, APC, BRCA1 and BRCA2 is generally produced by nucleotide mutations which lead to the synthesis of truncated proteins that are normally unfunctional (null mutations). However, most TP53 alterations, around 83% in NSCLC, behave as dominantnegative missense mutations. These alterations primarily involve amino acid residues contained in the central hydrophobic region of the protein (mostly included in exons 5 ± 8) which mediate the DNAspeci®c transactivating function of p53. Many researchers have focused their investigations on the potential value of p53 immunohistochemistry (IHC) as a prognostic tool (Quinlan et al., 1992; Navone et al., 1993; Carbone et al., 1994; Harpole et al., 1995; Lee et al., 1995; Passlick et al., 1995; Nishio et al., 1996) . The utility of IHC as a screening method is dubious, as null mutations (nonsense, frameshift and splice junction mutations) result in the production of shortened polypeptides and most are not recognized by speci®c antibodies because of antigenic site loss (Greenblatt et al., 1994) . Therefore, the use of PCRbased methods becomes compulsory if we are to ascertain the possible prognostic value of null mutations. We used PCR/SSCP analysis (Orita et al., 1989) followed by DNA sequencing to detect TP53 mutations. Fifteen (25%) of 59 Spanish cases contained mutations in exons 5 through 8 of TP53 gene, while such alterations were identi®ed in 12 (13%) of 92 Polish tumors (Table 2 and 5). Although much higher frequencies have been described in the literature (Table 5) , the relatively low incidence in the Spanish group is not so surprising if we compare it to previous reports as shown in Tables 5 and 6 (Ryberg et al., 1994; Law et al., 1995; Takagi et al., 1995; Liloglou et al., 1997) . Only one of these studies included non-smoking NSCLC patients (Takagi et al., 1995) , and, as re¯ected in Table 6 , the TP53 mutational occurrence seen in the Spanish cohort is not signi®cantly dierent from the frequencies reported by most investigators. We have no explanation for the low number of mutations found in the Polish cohort, but considering that both groups were equally determined, it may either re¯ect a random eect, or even that other non TP53 mutation mechanisms, may play a part in NSCLC progression. In this context, Miller et al. (1992) found that 30% of lung tumors examined harbored TP53 allelic losses without detectable point mutations at exons 4 through 8. Factors, other than TP53 gene mutations, may account for a greater part of NSCLC oncogenesis in cohorts with lower frequencies of TP53 mutation; the polymorphic VNTR region¯anking the H-RAS1 gene (Ryberg et al., 1994) and point mutations in the K-RAS proto-oncogene (Rosell et al., 1993 (Rosell et al., , 1996 are two examples. Kishimoto et al. (1992) and Casey et al. (1996) found higher frequencies, partly because they analysed exons 2 through 11, and one of these studies included perturbations found in SCLC patients in whom the occurrence of TP53 alterations is higher (Takahashi et al., 1991) . In the present study, the frequency of missense TP53 mutations was greater than the prevalence of null mutations (Table 2) . However, when the Polish population was observed, there was a scarcity of perturbations that lead to p53 ablation, since only one sample contained a nonsense mutation (1%). Nevertheless, null mutations made up 33% of the total number of mutations in the Spanish NSCLC tumors in contrast to lower frequencies documented by other investigators (Kishimoto et al., 1992; Lee et al., 1994; Ryberg et al., 1994; Takagi et al., 1995; Casey et al., 1996) .
Most of the DNA changes in the Spanish group were G?T transversions, 50% on the non-transcribed Table 6 Signi®cance levels (P) of pairwise comparisons of the TP53 mutational frequencies in dierent NSCLC populations using the Fisher Exact Test (2611 Table) Barcelona, Spain (Tables 3) , which are compatible with exposure to benzo(a)pyrene and to elevated levels of oxygen free radicals in the blood of cigarette smokers (Reid and Loeb, 1992) . The Polish samples contained more transversions than transitions. However, changes related to the exposure to dierent carcinogenic burden such as G?A transitions at non-CpG sites (40%), were the most frequent substitution in Polish patients, followed by G?T (27%) and G?C (27%) transversions (Table 5 ). This preponderance of nonCpG G?A transitions agree with the results obtained by Liloglou et al. (1997) in smoking NSCLC patients from Merseyside, UK, an industrialised region with a similar climate to that of Gdansk. The Polish tumor samples contained a high number of missense substitutions (75% of the total mutations), with most altering conserved amino acids belonging to domains IV and V. However, none of these mutations were located at codon 157, the most frequently described mutated site in LC. Forty-six percent of mutations were identi®ed at codons 245, 248 and 282, all of which are commonly mutated in human cancer. Amino acids 245 and 282 participate in the stabilization of the DNA binding surface of the protein, and some mutants aecting these codons alter p53 transcriptional activity and growth suppression (Greenblatt et al., 1994) . Nevertheless, none of the mutants changing amino acids 245 and 282 were the substitutions most commonly reported in LC (Greenblatt et al., 1994) . Amino acid 248, also a hotspot in LC, directly interacts with DNA, and it is assumed that missense changes at this position may aect the DNA-speci®c associated transcription of p53. Nevertheless, most TP53 missense mutations found in those tumors probably do not confer a growth advantage. The fact that there was no dierence in survival between the group of patients without mutations and those with missense mutations is not surprising if we keep in mind the fact that a signi®cant number of these mutants retain latent ability to bind DNA and still form tetramers. These data may help to explain why missense mutations found in this study did not result in major aggressiveness in this set of NSCLC patients. Moreover, no mutations were detected at residue Arg 273 which is probably involved in the allosteric regulation of the p53 tetramer. Interestingly, Japanese researchers found an association between mutations at the 273 hotspot and poor survival in NSCLC (Huang et al., 1997) .
Most TP53 missense mutations in the Spanish cohort were located outside the conserved regions (Table 3 ). This is not so novel, since other authors have found a similar trend in breast cancer in which some 55% of mutations were located outside domains II ± V (Sjogren et al., 1996) . Most TP53 hotspot codons are located within domains II ± V. However, there are some residues which are also relative hotspots lying outside these evolutionary conserved regions (151 ± 152, 157 ± 158, 163, 194 (Lys4Arg), 195 (Ile4Thr), 205, 220 and 266) . Two of eight Spanish patients (25%) had mutations outside the conserved domains which aected one of these codons (amino acid 151, Pro4Thr, Pro4Ser). The potential growth advantage of these perturbations in unknown, but considering that most mutations (67%) in the Spanish group changed no relevant amino acids, it seems plausible that these alterations may not aect the growth inhibitory pathway mediated by p53 in these NSCLC patients. Although, patients with null mutations had a poor clinical outcome, suggesting that p53 loss may confer a greater aggressiveness. However, the prognostic value of certain TP53 alterations in NSCLC and other cancers has yet to be completely elucidated. Many studies have used the IHC approach to ascertain the prognostic value of p53 accumulation, albeit with contradictory results, since IHC analysis is unable to detect most null mutations. Most investigators have only screened TP53 mutations aecting the central core of the protein and is believed that the combination of IHC plus DNA sequencing of exons 2 through 11 is mandatory in order to detect all p53 perturbations (Casey et al., 1996) . Functional assays in yeast to characterize the status of TP53 in tumors have recently been described (Inga et al., 1997; Lomax et al., 1997) . By using DNA sequencing methods, some authors have shown that null mutations as well as missense mutations aecting amino acids of the DNA-binding domain are equally associated with poor prognosis in breast cancer patients (Saitoh et al., 1994) . Our results prompted us to conclude that: (a) the low percentage of TP53 mutations aecting exons 5 ± 8 coding sequences in our study suggest that other mechanisms including TP53 allelic losses, alterations and/or aberrant expression of genes involved in the p53 mediated growth suppression pathway may exist in certain populations of NSCLC patients; (b) either ethnic disparities or dierent carcinogen burden may explain to some extent the distinct mutational pro®les of the two populations studied: G?A transitions at non-CpG sites were predominant in the Polish patients, and G?T transversions in the Spanish cohort; (c) missense mutations which do not perturb essential amino acids or generate certain hotspot mutants seem to be irrelevant in NSCLC prognosis; and (d) TP53 null mutations are linked to poor outcome in NSCLC. We believe that mechanisms other than TP53 missense and null mutations in the sequence-speci®c DNA binding region warrant investigation.
Materials and methods
Patients and DNA isolation
One hundred and ®fty-one patients surgically-resected with NSCLC, stages I to IIIa, according to the international TNM classi®cation (Mountain, 1986) were studied. All 151 patients for whom follow-up and tumor samples were available had undergone thoracotomy and resection between 1986 and 1992 as treatment of their disease. Data on LC recurrences and cause of death were obtained. Tumors were collected from 59 Spanish and 92 Polish NSCLC patients, the latter obtained through Gdansk School of Medicine.
Three to ®ve 5 mm tumor paran embedded sections were cut, microdissected from the surrounding normal tissue and collected in an eppendorf tube. To remove paran, 1 ml of xylene was added, centrifuged and rinsed with ethanol. After centrifugation, DNA from sections was extracted in a lysis buer (10 mM Tris-HCl pH 8.5, 2.5 mM MgCl 2 , 50 mM KCl, 0.5% Tween 20 containing 250 mg/ml of proteinase K) at 568C for 24 h. Then samples were centrifuged to clean them up. Supernatants were recovered, incubated at 958C for 10 min to inactivate proteinase K and used for ampli®cation.
PCR/SSCP (single-strand conformation polymorphism) and DNA sequencing
To analyse TP53 mutations (exons 5 ± 8), 1 ± 5 ml of the isolated genomic DNA sample were used as a template and ampli®ed in 10 mM Tris HCl (pH 9.0 at 258C), 50 mM KCl, 0.1% Triton X-100, 1.5 mM MgCl 2 , 200 mM of each dNTP and 0.5 mM of each amplimer (Navone et al., 1993) in a 50 ml volume. 1 ml of a 1/100 dilution of the PCR was used as a template for a 20 ml nested PCR reaction. DNA ampli®cation was performed in 10 mM Tris HCl (pH 9.0 at 258C), 50 mMKCl, 0.1% Triton X-100, 1.5 mM MgCl 2 , 200 mM dATP, 200 mM dTTP, 200 mM dGTP, 150 mM dCTP, 0.5 mCi (50 mM) of [a 32 P]-dCTP (Amersham Inc., UK), 0.5 mM of nested TP53 primers (Navone et al., 1993) in a 9600 Perkin-Elmer Cetus DNA thermal cycler. The thermal pro®le used was 948C for 1 min, 156(948C for 20 s, 568C for 20 s and 728C for 20 s), and 748C for 4 min. Two to four ml of the nested PCR reaction were mixed with an equal volume of denaturing solution (98% formamide, 10 mM EDTA pH 8.0, 0.02% xylene cyanol, 0.02% bromophenol blue). The DNA mixture was denatured at 958C for 5 min, chilled on ice and loaded onto a nondenaturing 6% polyacrylamide ± 16TBE gel containing 10% glycerol. Electrophoresis was performed at 4 W for 16 h at 48C, or alternatively at room temperature and cooled with a fan. The gel was dried and ®nally exposed to an autoradiographic ®lm (Kodak OAT, USA) using intensifying screens at 7808C for several hours and developed. Each experiment was repeated at least twice for each sample.
To determine the nature of TP53 mutations detected by SSCP technique, PCR products obtained from ampli®ed genomic DNA positive for SSCP were analysed by automated DNA cycle sequencing. Genomic DNAs were reampli®ed using speci®c primers for each exon and, PCR products were directly sequenced using the appropriate¯uorescent nested primer. For cycle sequencing, primers and primer dimers contained in the PCR ampli®ed product were previously removed by using S-300 HR Sephacryl microcolumns (Pharmacia Biotech, Uppsala, Sweden). Puri®ed PCR products were used as a templates in a cycle sequencing reaction using a¯uorescent nested primer (Pharmacia Biotech). Brie¯y, a cycle sequencing reaction for each nucleotide was performed using 500 ng of PCR template, 3 pmoles of a¯uorescent sequencing primer, dNTPs with the corresponding dideoxynucleotide, and 1.25 U Taq DNA polymerase in a sequencing buer containing MgCl 2 . First, DNA was denatured at 958C for 2 min and then 30 cycles of ampli®cation (958C 30 s, 56±658C 30 s, 728C 40 s) were performed followed by a soak pro®le at 48C. Then 4 ml of stop solution containing formamide and dextran blue was added, and the mixture was previously denatured at 958C for 3 min before loading into a prewarmed denaturing 6% polyacrylamide-8 M urea gel on an ALF express DNA sequencer. Samples were run at 40 W for 2 or 3 h and the sequencing data obtained were compared with the wild-type TP53 sequence. Independent PCR products obtained from each SSCP-positive genomic DNA sample were analysed at least twice to con®rm mutations.
Statistical analysis
For the purpose of statistical analysis the TP53 abnormalities were classi®ed into three major groups: no mutations, missense mutations and null mutations. The relationship among alterations of the TP53 gene and clinicopathological features was tested by the chi-square and Fisher exact tests. Also dierences in TP53 mutation frequency and pattern were examined with the same tests. To analyse the relationship between TP53 mutations and survival time of the patients, Kaplan ± Meier estimations as well as Log ± Rank and Tarone ± Ware tests were performed and mean survival times were computed according to Kaplan and Meier. The multivariate analyses were performed with the stepwise proportional hazards regression model for censored survival data (Cox's model).
